

SBRT offers curative option for lung cancer patients age 80 and older

March 16 2017

Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented today at the [2017 Multidisciplinary Thoracic Cancers Symposium](#). The advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.

While the primary treatment for early stage lung cancer is surgical removal of the tumor, some [patients](#) may not be able to tolerate surgery due to health status, advanced age or other factors. For these patients, the best curative option is SBRT, a specialized type of external beam RT that uses advanced imaging techniques to deliver extremely targeted radiation to a tumor. This high degree of precision makes SBRT particularly effective at sparing surrounding healthy tissue, which is important for tumor sites near essential organs, such as the heart and lungs. Patients complete SBRT treatment in three to five days, compared with several weeks for conventional RT.

"While multiple studies and trials have established the effectiveness of SBRT for inoperable early-stage lung cancer, one of the common reasons for not giving radiation in older patients is concern about tolerating the treatment and potential side effects," said Richard J. Cassidy III, MD, lead author of the study and a resident in radiation oncology at Emory University's Winship Cancer Institute in Atlanta.

"The low rates of side effects from SBRT for this [elderly population](#) in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early stage lung cancer."

Findings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015. All patients were age 80 or older at the time of their diagnosis, with a median age of 84.9 years. Forty percent of the tumors were adenocarcinomas, while 29 percent were squamous cell carcinomas and 31 percent did not have a biopsy. Fifty percent of patients who did not have a biopsy had a previous history of lung cancer. Researchers used logistic regression and proportional hazard testing to determine the association of patient, tumor and treatment characteristics to compare rates of survival, recurrence and progression and assess the influence of patient and disease characteristics. Recursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.

At two years following definitive SBRT for lung cancer among [elderly patients](#), survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS). CSS rates were higher for patients who were not active smokers but lower for patients who were older or had a previous lung cancer diagnosis (smoking Hazard Ratio (HR) = 0.14, $p = 0.03$; age HR = 1.19, $p = 0.04$; cancer HR = 7.75, $p = 0.01$). OS rates were higher for patients with higher Karnofsky Performance Status (KPS), which measures a patient's functional ability to perform ordinary tasks, such as work and self-care (HR = 0.91; p

Two-year estimates of local control and regional control were 84.5 percent and 71.7 percent, respectively. Local failure was more common among patients with adenocarcinomas (HR = 6.36, $p = 0.01$) and less common for patients with T1 tumors (HR = 0.20, p

"Our study, along with other studies, helps to show that SBRT can effectively and safely add years to the lives of elderly patients who have early stage lung cancer but cannot undergo an operation for it," said Dr. Cassidy. "Elderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age."

The abstract, "Stereotactic body radiotherapy for [early stage](#) non-small cell [lung cancer](#) in patients 80 years and older: A multi-center analysis," will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco.

Provided by American Society for Radiation Oncology

Citation: SBRT offers curative option for lung cancer patients age 80 and older (2017, March 16) retrieved 30 April 2024 from <https://medicalxpress.com/news/2017-03-sbrt-curative-option-lung-cancer.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--